References
- Al-Khalidi UA, Chaglassian TH. (1965). The species distribution of xanthine oxidase. J Biochem 97:318–20
- Beutler E. (1992). Cladribine (2-chlorodeoxyadenosine). Lancet 340:952–6
- Beutler E, Koziol J, McMillan R, et al. (1994). Marrow suppression produced by repeated dose of cladribine. Acta Haematologica 91:10–5
- Beutler E, Piro LD, Saven A. (1991). 2-Chloro-2C-deoxyadensine(2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymphoma 5:1–8
- Bierau J. (2004). Determination of the deoxycytidine kinase activity in cell homogenates with a non-radiochemical assay using reversed-phase high performance liquid chromatography. Identification of a novel metabolite of 2-chlorodeoxyadenosine. J Chromatogr B Analyt Technol Biomed Life Sci 805:339–46
- Bierau J, van Kuilenburg, André BP, et al. (2005). Nucleotide degradation. Chichester, UK: John Wiley & Sons Ltd
- Bojarska E. (1999). Electrooxidation of the antileukemic 2-chloro-2′-deoxyadenosine and related compounds. J Electroanal Chem 477:89–96
- Bonate PL. (1995). The distribution, metabolism, and elimination of clofarabine in rats. Drug Metab Dispos 33:739–48
- Bontemps F, Delacauw A, Cardoen S, et al. (2000). Metabolism and cytotoxic effects of 2-chloroadenine, the major catabolite of 2-chloro-2′-deoxyadenosine. Biochem Pharmacol 59:1237–43
- Carson DA, Wasson DB, Teatle R, et al. (1983). Specific toxicity of 2-chloro-deoxyadenosine towards resting and proliferating human lymphocytes. Blood 62:737–43
- Carson DA, Wasson DB, Beutler B. (1984). Anti-leukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci 81:2232–6
- Carson DA, Wasson DB, Esparaza LMCJ, et al. (1992). Oral anti-lymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′ deoxyadenosine. Proc Natl Acad Sci 89:1970–4
- Chabner BA, Ryan DP, Paz-Ares L, et al. (2001). Antineoplastic agents. Goodman and Gilman’s the pharmaceutical basis of therapeutics, 10th edn. New York: McGraw-Hill, 1389–459
- Else M, Dearden CE, Matutes E, et al. (2009). Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 145:733–40
- Food and Drug Administration. (2001). Guidance for industry: Bioanalytical method validation. Bethesda, MD: US Department of Health and Human Services, Food and Drug Administration
- Giovannoni G, Comi G, Cook G, et al. (2010). A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New Engl J Med 362:416–26
- Greyz N. (2004). Cladribine: from the bench to the bedside-focus on hairy cell leukemia. Expert Rev Anticancer Ther 4:745–57
- Leist TP, Weissert R. (2011). Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol 34:28–35
- Lindemalm S, Liliemark J, Juliusson G. (2004). Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. Cancer Lett 10:171–7
- Rice GP, Filippi M, Comi G. (2000). Cladribine and progressive MS clinical and MRI outcomes of a mutlicenter controlled trial. Neurology 54:1145–55
- Riscoe MK, Brouns MC, Fitchen JH. (1989). Purine metabolism is a target for leukemia chemotherapy. Blood Rev 3:162–73
- Saven A, Piro LD. (1992). Treatment of hairy cell leukemia. Blood 79:1111–20
- Seto S, Carrera CJ, Kubota M, et al. (1985). Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to non-dividing human lymphocytes. J Clin Invest 75:377–8
- Sipe JC, Romine JS, Koziol JA, et al. (1994). Cladribine in treament of chronic progressive mutiple sclerosis. Lancet 344:9–13
- Wu WN, McKnown LA, Moyer MD, et al. (1999). The in vivo metabolism of cladribine in the mouse, monkey and human. ISSX Proceedings of the 7th European ISSX meeting 14:91
- Wu WN, McKnown LA, Moyer MD, et al. (2004). Metabolism of the antineoplastic and immunosuppressive drug 2-CdA (Leustatin®) in animals and human. Xenobiotica 36:591–606